

**AMENDMENTS TO THE CLAIMS**

This listing of the claims will replace all prior versions, and listings, of claims in this application.

***Listing of Claims***

1-36. (Canceled)

37. (Currently Amended) A method for treating septic shock syndrome in a mammal, the method comprising administering to the mammal an effective amount of an antibody which comprises a sequence represented by SEQ ID NO: 4, or fragment thereof, that binds native human tissue factor to form a complex, whereby factor X binding to the complex is inhibited and factor VII or VIIa binding to tissue factor is not inhibited.

38. (Canceled)

39. (Previously Presented) The method of claim 37, wherein the antibody is a monoclonal antibody.

40. (Previously Presented) The method of claim 37 wherein the antibody is a chimeric antibody.

41. (Previously Presented) The method of claim 40, wherein the antibody comprises a constant region of human origin.

42. (Previously Presented) The method of claim 37, wherein the antibody is a single chain antibody.

43. - 46. (Canceled)

47. (Previously Presented) The method of claim 37, wherein the antibody is humanized.

48. (Previously Presented) The method of claim 47, wherein the antibody is a humanized chimeric antibody.

49. (Previously Presented) The method of claim 47, wherein the antibody comprises human variable regions.

50. (Previously Presented) The method of claim 37 or 47, wherein the antibody is an immunologically active antibody fragment.

51. (Previously Presented) The method of claim 50, wherein the fragment is a Fab, F(v), Fab' or F(ab)<sub>2</sub> fragment.

52. (Previously Presented) The method of claim 37 or 47, wherein Factor X binding to the complex is inhibited by at least about 80 percent in a standard in vitro binding assay.

53. (Previously Presented) The method of claim 52, wherein the Factor X binding to the complex is inhibited by at least about 90 percent in a standard in vitro binding assay.

54. (Previously Presented) The method of claim 53, wherein the Factor X binding to the complex is inhibited by at least about 95 percent in a standard in vitro binding assay.

55. (Previously Presented) The method of claim 37, wherein the mammal is a human patient who has or is suspected of having septic shock syndrome.